KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA (2016 - 2025)

Historic EBITDA for Medpace Holdings (MEDP) over the last 11 years, with Q4 2025 value amounting to $160.2 million.

  • Medpace Holdings' EBITDA rose 2087.34% to $160.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $562.1 million, marking a year-over-year increase of 1842.45%. This contributed to the annual value of $562.1 million for FY2025, which is 1842.45% up from last year.
  • Latest data reveals that Medpace Holdings reported EBITDA of $160.2 million as of Q4 2025, which was up 2087.34% from $148.6 million recorded in Q3 2025.
  • Medpace Holdings' 5-year EBITDA high stood at $160.2 million for Q4 2025, and its period low was $46.4 million during Q2 2021.
  • For the 5-year period, Medpace Holdings' EBITDA averaged around $95.5 million, with its median value being $91.4 million (2023).
  • Per our database at Business Quant, Medpace Holdings' EBITDA soared by 80.42% in 2021 and then soared by 4329.14% in 2022.
  • Medpace Holdings' EBITDA (Quarter) stood at $59.0 million in 2021, then soared by 38.04% to $81.5 million in 2022, then rose by 15.02% to $93.7 million in 2023, then soared by 41.37% to $132.5 million in 2024, then grew by 20.87% to $160.2 million in 2025.
  • Its EBITDA stands at $160.2 million for Q4 2025, versus $148.6 million for Q3 2025 and $133.1 million for Q2 2025.